Seeking Alpha

Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

CNM-Au8 ® treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) Clene (CLNN) plans to discuss the totality of the survival ...
Hosted on MSN

Tukey’s (1-way ANOVA): See the Difference in Your Data Sets

ANOVA will tell you whether there is a statistically significant difference in the population means of three or more groups of data. But which means are different? Tukey’s will tell you that. Analysis ...
Nasdaq

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured ...
MarketWatch

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and ...

The MarketWatch News Department was not involved in the creation of this content. -- Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney ...
The American Journal of Managed Care

Meta-Analysis Finds No Significant NSCLC Survival Differences With ICIs, but Trial Diversity Remains Limited

More representative trial populations and standardized subgroup reporting are needed in non–small cell lung cancer (NSCLC) research, according to a meta-analysis published in Cancers, which found no ...
Seeking Alpha

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that ...